(Q37937869)

25 August 2017

1 reference

title

Experimental models for the development of new medical treatments in prostate cancer (English)

1 reference

25 August 2017

1 reference

Anne Chauchereau

1

1 reference

25 August 2017

publication date

1 September 2011

1 reference

European Journal of Cancer

25 August 2017

published in

1 reference

25 August 2017

volume

47 Suppl 3

1 reference

25 August 2017

page(s)

S200-14

1 reference

Serially heterotransplanted human prostate tumours as an experimental model

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Quantitation of apoptotic activity following castration in human prostatic tissue in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Development and characterization of efficient xenograft models for benign and malignant human prostate tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Tissue slice grafts: an in vivo model of human prostate androgen signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Genetically modified mice and their use in developing therapeutic strategies for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Modeling prostate cancer: a perspective on transgenic mouse models

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Molecular genetics of prostate cancer: new prospects for old challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

STUDIES ON PROSTATIC CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Molecular determinants of resistance to antiandrogen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Androgen-repressed phenotype in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Androgen receptor expression in androgen-independent prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

LuCaP 35: A new model of prostate cancer progression to androgen independence

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Use of nude mouse xenograft models in prostate cancer research

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Update in the management of patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Molecular biology of bone metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Differential experimental micrometastasis to lung, liver, and bone with lacZ-tagged CWR22R prostate carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Spiculated periosteal response induced by intraosseous injection of 22Rv1 prostate cancer cells resembles subset of bone metastases in prostate cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Bone-specific growth inhibition of prostate cancer metastasis by atrasentan

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Bioluminescent imaging study: FAK inhibitor, PF-562,271, preclinical study in PC3M-luc-C6 local implant and metastasis xenograft models

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Targeting the α Receptor for Platelet-Derived Growth Factor as a Primary or Combination Therapy in a Preclinical Model of Prostate Cancer Skeletal Metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Drug resistance in metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Microtubules and resistance to tubulin-binding agents

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Gene expression profiling of the androgen independent prostate cancer cells demonstrates complex mechanisms mediating resistance to docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Stem cells, cancer, and cancer stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

A luminal epithelial stem cell that is a cell of origin for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Prospective identification of tumorigenic prostate cancer stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Identification of a cell of origin for human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Revisiting the concept of cancer stem cells in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Stem cell characteristics in prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Isolation of a human prostate carcinoma cell line (DU 145)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Prostate stem cell antigen is overexpressed in prostate cancer metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Cancer stem cells in radiation resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

Radiotherapy augments the immune response to prostate cancer in a time-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970166-6

7 January 2021

10.1016/S0959-8049(11)70166-6

Identifiers

DOI

1 reference

25 August 2017

1 reference